2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Wednesday, November 8, 2017

11:00AM-12:30PM: Abstract Number: 2942

One Year Changes in Ultrasound Findings in the Feet Are Associated with Patient Reported Outcomes but Not Clinical Examination: a Prospective Observational Study of Patients with Early Rheumatoid Arthritis

Imaging of Rheumatic Diseases II: Focus on Rheumatoid Arthritis and Systemic Sclerosis

11:00AM-12:30PM: Abstract Number: 2940

Outcome of Power Doppler Ultrasound-Detected Residual Synovitis in Rheumatoid Arthritis Patients with Clinical Remission: A 1 Year Longitudinal Study with Consecutive Ultrasound Examinations

Imaging of Rheumatic Diseases II: Focus on Rheumatoid Arthritis and Systemic Sclerosis

11:00AM-12:30PM: Abstract Number: 2978

OX40/OX40L Axis Impairs Follicular and Natural Regulatory T Cell Function in Human Systemic Lupus

Systemic Lupus Erythematosus – Human Etiology and Pathogenesis II

11:00AM-12:30PM: Abstract Number: 2944

Patterns and Characteristics of Accelerated Hand Osteoarthritis: Data from the Osteoarthritis Initiative

Osteoarthritis – Clinical Aspects II: Structural Progression and Incidence

11:00AM-12:30PM: Abstract Number: 2984

Predictive Value of a Combined Index for Weight Loss in Systemic Sclerosis

Systemic Sclerosis, Fibrosing Syndromes and Raynaud's – Clinical Aspects and Therapeutics III

11:00AM-12:30PM: Abstract Number: 2983

Predictors for Disease Worsening Defined By Organ Failure in Diffuse Systemic Sclerosis: A European Scleroderma Trials and Research (EUSTAR) Analysis

Systemic Sclerosis, Fibrosing Syndromes and Raynaud's – Clinical Aspects and Therapeutics III

11:00AM-12:30PM: Abstract Number: 2951

Responsiveness of the Patient Reported Outcomes Measurement Information System to Golimumab Intravenous and Infliximab Treatment in a Real World Clinical Trial in Rheumatoid Arthritis Patients

Patient Outcomes, Preferences, and Attitudes III

11:00AM-12:30PM: Abstract Number: 2972

Risk of Myocardial Infarction and Cerebrovascular Accident in Ankylosing Spondylitis: A General Population-Based Study

Spondyloarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment V

11:00AM-12:30PM: Abstract Number: 2963

Sirukumab Improves Synovial Vascularity As Measured By Power Doppler Sonography in Rheumatoid Arthritis Patients from As Early As Week 4 in a Phase 3 Trial

Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy V: Imaging and Cardiovascular Outcomes Therapy

11:00AM-12:30PM: Abstract Number: 2964

Structural Damage in Patients with Very Early RA Is Predicted with Clinical Measures of Baseline Disease Activity: DAS28 (CRP), SDAI, M-DAS28 and RAPID3 but Not CDAI

Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy V: Imaging and Cardiovascular Outcomes Therapy

11:00AM-12:30PM: Abstract Number: 2979

The Expression of Mitochondrial Molecules in Microparticle Immune Complexes in the Blood of Patients with Systemic Lupus Erythematosus

Systemic Lupus Erythematosus – Human Etiology and Pathogenesis II

11:00AM-12:30PM: Abstract Number: 2949

The Relation of Cumulative Load to Prevalent Cartilage Damage in the Knee

Osteoarthritis – Clinical Aspects II: Structural Progression and Incidence

11:00AM-12:30PM: Abstract Number: 2943

Ultrasound Scoring of One Parotid and One Submandibular Gland in Primary Sjogren’s Syndrome – Further Increasing Feasibility in Outpatient Clinics

Imaging of Rheumatic Diseases II: Focus on Rheumatoid Arthritis and Systemic Sclerosis

11:00AM-12:30PM: Abstract Number: 2975

Using Immune and Metabolic Phenotyping to Understand the Immunopathogenesis of Juvenile-Onset SLE and Stratify Patient Groups

Systemic Lupus Erythematosus – Human Etiology and Pathogenesis II

11:00AM-12:30PM: Abstract Number: 2950

Validation of a Definition for Flare in Patients with Established Gout

Patient Outcomes, Preferences, and Attitudes III

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].